Intensity Therapeutics reports Q3 net loss $2.3M; INT230-6 shows 93% disease control in sarcoma

INTENSITY THERAPEUTICS, INC.

2023-Q3 EPS reported -$1.26

Phase 1/2 INT230-6 data in refractory soft tissue sarcoma: 93% disease control rate, survival extension ~15 months vs synthetic control.
Received Orphan Drug Designation for all three components of INT230-6 for soft tissue sarcoma.
Completed upsized IPO with full over-allotment, net proceeds $20.2M; cash $15.6M as of Sept 30, 2023.
R&D expenses $1.4M, G&A $1.1M; net operating loss $2.3M for Q3 2023.
On track to file IND for Phase 3 study in sarcoma and report Phase 2 breast cancer results by end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.